B. Riley raised the firm’s price target on Cognition Therapeutics (CGTX) to $3 from $2 and keeps a Buy rating on the shares. Cognition’s Phase 2 START trial for early Alzheimer’s has fully enrolled 540 patients, reinforcing momentum from prior positive Phase 2b results and rising investigator interest in oral zervimesine, the analyst tells investors in a research note. With an 18-month primary endpoint and allowance for combination therapy, the trial design offers meaningful de-risking ahead of a mid-to-late 2027 readout, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine
- Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment
- Cognition Therapeutics Advances Alzheimer’s Drug Development
- Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)